What would it take to make a diabetic foot ulcer close? A €2.9 million round in Umeå on 1 October is a serious answer, and it is still not a result.
Omnio AB, in Umeå, closed an oversubscribed €2.9 million round — roughly $3.8 million — from existing investors and shareholders. The money covers a master cell bank, a GMP batch, the toxicology studies that gate a trial application, and a Phase I/IIa study in diabetic foot ulcers. Patient studies are pencilled in for 2027, and CEO Felipe Velasquez says the company is already evaluating contract research organisations, investigators and trial countries across Europe.
The target is recombinant plasminogen, built on Professor Tor Ny's research at Umeå University, where he also heads R&D at Omnio. Diabetic foot ulcers have been regenerative medicine's standing test case for three decades, and they have broken most mechanisms that once looked convincing in a mouse.
The floor under a wound that will not close
A chronic wound is not a slow wound. It is a wound sitting on a floor, and the floor is built out of the body's own housekeeping enzymes running out of control.
Protease profiling has made that floor unusually legible. Wound fluid carries distinct cleavage signatures that separate ulcers destined to heal from ulcers that will not, and mass spectrometry is now good enough to cluster those peptides and read infection status off a sample. The clinical stakes are just as legible in the trial registry: a 242-patient randomised trial of a topical desiccant gel in ulcers of four weeks or more, with complete healing at twenty weeks as the endpoint.
The mechanism underneath is specific enough to invest against. Deficiency of an endogenous serine peptidase inhibitor prolongs neutrophil infiltration and lifts proteolytic activity across two enzyme families at once — plasminogen activators and matrix metalloproteinases. Closure stalls while that imbalance persists, and modulating inhibitor levels restores the balance and lets repair resume.
That is the whole commercial case for recombinant plasminogen: replenish the missing switch, and the wound walks back down its own healing cascade. Omnio's candidate does exactly that, which is a lower-risk proposition than it sounds. It installs no novel pathway. It restocks a pathway the patient already runs, and Umeå University is the group that characterised the imbalance it aims to correct.
The floor is also why the field is crowded. Casein-film dressings now sense and moderate protease activity inside the wound, and five separate programmes are aimed at the same twenty-week endpoint.
Diabetic foot ulcer incidence
Chronic foot ulcers affect up to 25% of people with diabetes, and delayed healing is the primary pathophysiological factor behind amputation. · clinicaltrials.gov, 2026
Annual US treatment burden
A peer-reviewed estimate put the annual US cost of diabetic foot ulcer treatment above $2 billion. · Peer-reviewed review, 2019
Position one: the mechanism reset is real
Start with what changed at Omnio rather than what was claimed. Two financings are on the record: EUR 4.3 million in spring 2025, and EUR 2.9 million this month. The size of the cheque is not the argument. The sequence is what it buys — a master cell bank established, a GMP batch in scale-up, and toxicology studies named as the next spend. Those are the unglamorous steps that sit between a laboratory result and an investigational new drug application, and this company has now funded three of the four.
The independent protease literature also gives the thesis support Omnio did not have to commission. The imbalance between serine peptidase inhibitors, plasminogen activators and matrix metalloproteinases has been characterised in human non-healing ulcers, with cleavage signatures specific to wounds that stall. Omnio is aiming at a documented biochemical lesion with a documented restorative intervention.
✔ The case for the mechanism
+ The protease imbalance behind non-healing ulcers is characterised in human wound fluid, independently of Omnio
+ The spring 2025 EUR 4.3M round preceded this one, and the master cell bank is now built
+ CROs, investigators and trial countries across Europe are already under evaluation for 2027
What would confirm it: a trial application filed in Europe before the Q1 2027 raise, and a first patient dosed inside 2027.
Position two: a preclinical mechanism is not a market
The counterweight is the field's own record, and it is not encouraging. A 2026 pathophysiology review of diabetic foot ulceration lays out the interacting causes — peripheral neuropathy, vascular insufficiency, impaired immune response — and a JAMA review treats the ulcer through a combined wound, ischemia and infection framework, with debridement, pressure relief and treatment of ischemia and infection as first-line therapy. Thirty years of accumulated attempts produced a standard of care that is still a scalpel, an offloading device and a dressing.
The nearest precedent is instructive. A peptide called DSC127, an angiotensin (1–7) analogue, ran a randomised, double-blind, placebo-controlled Phase 2 in diabetic foot ulcers, and the published result in Wound Repair and Regeneration was preliminary evidence that it was safe and accelerated healing. That is a real trial with a real readout, and standard of care did not change. Mechanism plus Phase 2 is where most of these programmes go to be remembered rather than prescribed.
Then there is the balance sheet next door. FibroBiologics dosed the first patients in its Phase 1/2 CYWC628 trial in diabetic foot ulcers and reported $3.5 million in cash on hand at 30 June 2026. That is a lean programme running straight at an interim readout in the second half of 2026, in a wound type the company itself describes as stubbornly resistant to durable solutions after decades of clinical effort.
And Omnio's own calendar argues the same way. This round funds a master cell bank, a GMP batch and toxicology work. The clinical programme is a Phase I/IIa of safety and early efficacy, targeted for 2027, with the next raise pencilled in for Q1 2027 to fund it through first efficacy data. No human efficacy number exists for this molecule. The €2.9 million buys the right to ask the question, and the Q1 2027 round will be priced against an answer nobody has yet seen.
✗ The case against
− Delayed healing is the primary driver of amputation and death, which makes it a high-value target and a graveyard at the same time
− The nearest clinical competitor reported $3.5 million in cash at 30 June 2026 and faces a readout under pressure
− The round that just closed funds toxicology, not patient data
What would refute it: an accepted toxicology package with a filed application, on a schedule that survives the Q1 2027 financing.
The wound care field's ceiling is set by biology and payment at the same time, and the mechanism argument only settles half of it.
The nearer risk to Omnio is not a competitor's science. It is the reimbursement calendar running on a separate track and arriving first.
Who else is solving this, and with what
| Programme | Approach | Where it stands | Next disclosed milestone |
|---|---|---|---|
| Omnio (Umeå) | Recombinant plasminogen | Preclinical; €2.9M raised 1 Oct 2026 | Phase I/IIa in DFU, 2027 |
| FibroBiologics CYWC628 | Biologic, diabetic foot ulcers | Phase 1/2; $3.5M cash at 30 Jun 2026 | Interim data, H2 2026 |
| VELGRAFT (NCT07498218) | Allogenic stem-cell and adipocyte construct | Phase 1, started 11 Mar 2026 | Enrolment and safety readout |
| DEBRICHEM (NCT07206862) | Topical desiccant gel | 242 patients randomised | Complete healing at 20 weeks |
| AOTI TWO2 | Topical wound oxygen | Marketed device; AOTI reports a proposed LCD | CMS decision, within a year (per AOTI) |
Stage and cash figures as disclosed by each company or registry entry, September–October 2026.
The table is the honest version of the opportunity. Five groups, five different modalities, one shared endpoint: twenty-week or better healing in ulcers that conventional care cannot close. Only one of them is built on a mechanism its own university group characterised. Only one has no human data. The entry with the deepest mechanistic story is also the furthest from a readout, and the entry closest to a coverage decision is selling oxygen through a topical foam.
From the archive: this is the 21st Biotech & Health deal in our last 100 published. Sixteen days ago we wrote about HexemBio's $15.5M bet on stem cells in a synthetic yolk sac — a different mechanism, the same wager on biology that has to work in a human.
The clock this round does not mention
Here is the variable that decides whether €2.9 million becomes a product, and it is not a molecule. Recurrence is why the coverage question exists at all: a JAMA review of the field puts recurrence after healing at 42% at one year and 65% at five years. Against that, AOTI says it has a proposed CMS Local Coverage Determination in draft for its TWO2 topical wound oxygen therapy, aimed at diabetic foot ulcers that have failed four weeks of optimised care. By the timetable AOTI describes, a 45-day public comment period runs first and CMS then finalises the determination within a year. AOTI also reports an 88% reduction in diabetic foot ulcer recurrence across its randomised and real-world evidence.
Read that against Omnio's timetable. The coverage decision on an incumbent topical oxygen therapy lands inside twelve months. Omnio's first patient data lands in 2027, and its next financing is scheduled for Q1 2027 to fund that study. If the determination lands first, the reimbursement pathway for the four-week non-healing cohort is defined by a device already on the market, and anyone arriving after it inherits a category instead of opening one.
That asymmetry is why the round reads as both late and early. Late, because the payment question is being answered now by someone else. Early, because a biologic that re-supplies the missing protease switch has never been tested in a human diabetic foot ulcer, and nothing in the €2.9 million changes that.
What would settle it
Four things, none of them a press release. A toxicology package accepted and a trial application filed in Europe before the Q1 2027 raise, because that separates a company with a schedule from one with a plan. A named contract research organisation and a named trial country, which converts "we are evaluating" into a protocol. A first patient dosed inside 2027, the only event that reprices anything for an investor. And a coverage decision, in the United States or any national route, naming wound therapy as billable for the non-healing cohort.
The Q1 2027 raise gets priced against a coverage deadline that expires a year earlier than the patient data. This round funds the question. The next one funds the answer, and it is scheduled before the answer exists.
This financing demonstrates our continuous progress and strong confidence from our current investors. Their support allows us to continue the development and puts us in a stronger position ahead of our next financing round for clinical studies.— Felipe Velasquez, CEO, Omnio AB
Velasquez is describing a company that has funded the unglamorous steps in the order they need to happen. Whether the round is good news for the economics depends on whether a recombinant plasminogen can be shown to close a diabetic foot ulcer, and on whether anyone will pay for it when it does.